Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quabodepistat 4- vs 6-month regimens for rifampicin-resistant/multidrug-resistant pulmonary tuberculosis
CTR20260164Phase 3Active
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of quabodepistat in pulmonary tuberculosis (TB), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Jan 2026; status: active.
02
Drugs
quabodepistat
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on CTR20260164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260164.